Clinic Stuff

Long Standing DADS Variant of CIDP 4/5 of intrinsic hand and foot muscles. He had diffuse Preceding AL : A sentinel event areflexia, impaired large and small fiber sensation distally or serendipitous association? and a positive Romberg test. He also had postural tremor Deepak Menon1 MD, Sara Alnajjar1 MD, Vera Bril1 of both hands persisting on intentional movements. The MD, FRCP(C) nerve conduction studies during the first visit revealed a 1Ellen & Martin Prosserman Centre for demyelinating severe sensorimotor . (Table Neuromuscular Diseases, University Health Network, 1) University of Toronto, Toronto, Canada Prior investigations showed a CSF protein of 128gm/L and normal laboratory tests including CBC, ESR, renal Keywords: chronic inflammatory demyelinating polyneu- function, vitamin B12, glycosylated hemoglobin, 2-hour ropathy, distal acquired demyelinating symmetric neuropa- glucose tolerance test, serum protein electrophoresis, thy, monoclonal gammopathy of unknown significance, amy- serum immunoelectrophoresis, levels of IgG, IgA and IgM, loidosis, free light chain assay and anti MAG level. A sural nerve biopsy reviewed with a neuropathologist showed an inflammatory neuropathy with marked loss of myelinated nerve fibers, hypermyelinated Introduction fibres, scattered CD45+ lymphocytes and occasional Diagnosis, treatment and long-term term monitoring CD68+ macrophages consistent with CIDP. Congo red of patients with chronic inflammatory neuropathies can be staining did not reveal any amyloid deposition. difficult with many pitfalls. This is particularly true when A diagnosis of CIDP was made and he was started patients on immunomodulatory therapy (IMT) worsen as on prednisone and propranolol for tremor. He stopped the worsening could be due to a relapse, emergence of an progressing, his balance normalized and his dexterity associated or unrelated disorder or due to an error in the improved although not back to normal and he had to change primary diagnosis. Primary amyloidosis (AL) is often called his career. Whenever steroid tapering was attempted, the ‘great imitator’ due to its indolent and multisystemic he had worsening of symptoms and function. Low dose presentation and is often the least considered amongst the prednisone was continued and IVIG added. He remained heterogeneous spectrum of paraproteinemic neuropathies. on this maintenance therapy and was doing well clinically [1] When a paraproteinemia is encountered during and electrically. The nerve conduction studies done in evaluation of neuropathy, failing to think beyond MGUS can eleven years from the baseline were somewhat improved delay the diagnosis of AL until so advanced that treatment compared to baseline. (Table 1) Any attempts at increasing is ineffective.[2] Here we present a case of a patient with IVIG intervals or reducing dosage was met with worsening idiopathic distal acquired demyelinating symmetric symptoms. Trials of cyclophosphamide, azathioprine and neuropathy (DADS-I) who succumbed to AL after two rituximab as steroid-sparing agents failed. After 18 years, decades. We explore the association of AL neuropathy with the patient deteriorated despite maintenance steroid and DADS, both paraprotein-related neuropathies. IVIG and was re-investigated. (Table 2) Laboratory testing showed a monoclonal peak of IgG lambda with M protein Case Report level of 10gm/L with a second value about 8 months later of A 35-year-old dentist presented with a two-year 11gm/L. Within six months, he developed progressive pedal history of insidious numbness and paresthesia over the toes, edema and was diagnosed with nephrotic syndrome. Renal feet and fingertips. These symptoms progressed to include biopsy showed mild to moderate mesangial expansion unsteadiness of gait, loss of distal dexterity and hand by pale staining material which was also found in vessel tremors preventing him from performing his job. He did walls and which stained positive with Congo red stain, not have pain, autonomic symptoms or any constitutional and immunofluorescent microscopy showed IgG lambda complaints. His family history was notable for an unusual deposits. With a positive family history of neuropathy, sensorimotor polyneuropathy in his father who also had genetic studies were performed for an autosomal dominant IgG paraproteinemia and an elevated CSF protein. The hereditary amyloidosis and no pathogenic variants were neurological examination showed mild distal weakness found in (transthyretin) TTR, fibrinogen alpha chain (FGA), with MRC grade 4+/5 power in ankle dorsiflexion and lysozyme (LYZ) and ApoA1 genes. He was treated with cyclophosphamide and bortezomib and later lenalidomide RRNMF Neuromuscular Journal 2021;2(2):41-45 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 41 No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/) Clinic Stuff

Table 1. Motor nerve conduction studies during the course of illness Latency Velocity (m/s) Amplitude (mv) Time in years 0 11 18 0 11 18 0 11 18 Median nerve APB Wrist 6.7 5.9 5.4 9.6 12.3 8.2 Elbow 15.8 15.7 16.2 27 27 24 5.6 7.3 4.3 Axilla 18.8 19.2 19.4 33 36 30 4.9 7.2 4.1 Peroneal nerve EDB 10.0 8.8 10.3 1.5 1.8 0.2 Ankle Fibular head 28.2 25.3 25.3 17 18 20 0.2 1.2 0.1 Popliteal fossa 32.3 30.2 29.7 20 20 20 0.3 1.1 0.1 Peroneal nerve TA Fibular head * 5.4 6.0 * 12.0 5.2 Popliteal fossa * 8.8 9.5 * 11.6 4.9 APB- abductor pollicis brevis, EDB- extensor digitorum brevis, TA- tibialis anterior, * not done without response. He underwent autologous bone marrow in the extracellular tissue, and can either be localized or transplantation in, but his condition was complicated by systemic, acquired or inherited.[5] AL or primary systemic cardiomyopathy and bilateral pulmonary emboli. At the last amyloidosis arises due to the deposition of monoclonal clinic visit, he had mild distal motor weakness, sluggish to immunoglobulin light chain which in turn is produced by absent reflexes and significant loss of sensation affecting a clonal plasma cell expansion. In fact AL is a plasma cell ambulation and was wheelchair-bound. He had subsequent dyscrasia along the same lines as multiple myeloma (MM), worsening with sepsis, progressive cardiac and renal and the pathogenic mechanism which leads the clonal dysfunction and succumbed to his illness within 2 years of expansion down the path to MM or to systemic amyloidosis the neurological deterioration. Figure 1 outlines his disease remains unknown.[6,7] is seen in course and treatment. 17 to 35% of AL patients and is not a common presenting symptom, but when it is, the diagnosis of AL is significantly delayed.[8–10] While the commonest neuropathic Discussion presentation is sensory predominant neuropathy with The current report highlights a case of DADS-I variant autonomic symptoms resembling hereditary transthyretin of CIDP initially responsive to IMT for almost two decades. amyloidosis, presentations including cranial neuropathies, Late in the course, paraproteinemia was detected and was lumbosacral plexopathies, mononeuropathies and CIDP confirmed to be due to AL. This case raises several complex have been described.[11–16] questions about the long-term monitoring of inflammatory However, it does not appear that our patient had AL and paraproteinemia associated neuropathies. presenting as a DADS variant of CIDP at onset. The patient The cornerstone in the evaluation of neuropathy is had a phenotype most suggestive of DADS and never had the appropriate classification of the syndrome based on any autonomic symptoms. In addition, the absence of clinical phenotype, nerve conduction studies and laboratory amyloid deposits but rather features consistent with CIDP investigation. Since the initial description by Katz et al in in the nerve biopsy, a positive response both clinically early 2000 of the distinct distal sensory predominant and electrically with IMT and a duration of illness spread neuropathy associated with M protein, the spectrum of over two decades do not appear to be consistent with a paraproteinemic neuropathy has expanded.[3,4] . SPEP CIDP-like presentation of AL. The diagnosis of AL in this and SIEP are usually ordered and if a paraproteinemia is case was made after reinvestigation prompted by clinical detected, both physician and patient are often reassured that deterioration after many years of stability on IMT. the diagnosis is MGUS and paraproteinemic neuropathy. When evaluating and monitoring patients with However, another plasma cell dyscrasia which is often paraproteinemia, besides progression to MM it has to be missed is AL. Amyloidosis refers to a group of conditions borne in mind that all forms of MGUS can potentially in which misfolded insoluble protein fibrils with unique progress to AL. [17] In a series from the Mayo Clinic, 9% of beta pleated structure and staining properties accumulate

RRNMF Neuromuscular Journal 2021;2(2):41-45 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 42 No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/) Clinic Stuff

Figure 1. Timeline of disease course all patients with a monoclonal gammopathy were ultimately prompt re-investigation until the patient had worsening proven to have light chain amyloidosis.[18] Features that of neuropathy. Although the patient had the DADS demand special attention include predominantly axonal phenotype, he had been evaluated for M protein previously polyneuropathy, bilateral CTS, debilitating symptoms and with negative results. Whether initial titres were too low for rapid neuropathy progression. Many AL characteristic detection by the then standard assays, or whether patients systemic symptoms and signs, such as periorbital purpura, with DADS-I require frequent monitoring for development macroglossia and shoulder pad signs, are seen only in a of paraproteinemia are questions that remain unanswered minority of AL patients.[1,5,19] Evaluation should include at present. Although there is no conclusive proof, the final free light chain (FLC) assay and kappa:lambda ratio in worsening of neuropathy in this case is likely related to addition to the SIEP and SPEP. Negative SPEP, SIEP development AL. Interestingly, a recent large population and FLC in serum and urine effectively rule out AL.[5] based study showed that MGUS conferred a 2.9 fold Direct organ biopsy is rarely needed, and less invasive increased risk of progression to AL when associated with investigations such as abdominal fat aspiration, lip or rectal peripheral neuropathy.[21] The majority of cases with biopsy and immunohistochemistry or mass spectroscopy MGUS-related neuropathy progressing to AL do so within are useful to identify amyloid protein. Recommendations the first year which is consistent with the course in our for monitoring of patients with MGUS is risk stratified patient. based on quantity and type of M protein and FLC ratio. The family history of an unusual neuropathy related High risk patients need extensive evaluation including bone to paraproteinemia and its significance also remains marrow biopsy not only to look for evidence of malignancy unexplained. We found one report of a similar father- but also for AL.[20] son presentation, so a rare genetic mechanism might be Unfortunately, our patient developed systemic responsible.[22] manifestations of AL within a short interval from the The diagnosis of MGUS opens a window of opportunity detection of paraproteinemia, and had a rapid downhill to the diagnosis of AL since virtually all cases of AL are course despite and bone marrow transplant. preceded by MGUS. This is particularly true in the setting This rapid decline makes one suspect that the patient had of a neuropathic presentation since there is increased risk of a paraproteinemia for some time, but there was nothing to progression of MGUS to AL with such an association. Since

RRNMF Neuromuscular Journal 2021;2(2):41-45 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 43 No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/) Clinic Stuff an M protein is associated with 50-70% of DADS cases, it 7. Merlini G, Palladini G. Differential diagnosis of may be worthwhile to monitor all DADS patients for AL monoclonal gammopathy of undetermined significance. frequently, even if the initial testing is negative. The need Hematology 2012;2012:595–603. https://doi.org/10.1182/ for FLC and kappa:lambda ratio along with the assessments asheducation.V2012.1.595.3798563. SPEP and SIEP in serum and urine in screening and 8. Duston MA, Skinner M, Anderson J, Cohen monitoring MGUS patients has to be stressed. Finally, when AS. Peripheral neuropathy as an early marker of AL a patient with CIDP who is doing well on IMT fails, the amyloidosis. Arch Intern Med 1989;149:358–60. novel development of MGUS or AL should be considered. 9. Kaku M, Berk JL. Neuropathy Associated with Systemic Amyloidosis. Semin Neurol 2019;39:578–88. https://doi.org/10.1055/s-0039-1688994. Corresponding author: 10. Rajkumar SV, Gertz MA, Kyle RA. Prognosis of Vera Bril, 5EC-309, patients with primary systemic amyloidosis who present Toronto General Hospital, 200 Elizabeth St., with dominant neuropathy. Am J Med 1998;104:232–7. Toronto, ON, Canada, M5A 4H9 https://doi.org/10.1016/s0002-9343(98)00037-0. [email protected] 11. Matsuda M, Gono T, Morita H, Katoh N, Kodaira M, Phone: 1-416-340-3315 Ikeda S. Peripheral nerve involvement in primary systemic Fax: 1-416-340-4189 AL amyloidosis: a clinical and electrophysiological study. Eur J Neurol 2011;18:604–10. https://doi.org/10.1111/ References j.1468-1331.2010.03215.x. 1. Vaxman I, Gertz M. When to Suspect a Diagnosis 12. Traynor AE, Gertz MA, Kyle RA. Cranial of Amyloidosis. AHA 2020;143:304–11. https://doi. neuropathy associated with primary amyloidosis. org/10.1159/000506617. Ann Neurol 1991;29:451–4. https://doi.org/10.1002/ 2. Karam C, Moshe-Lilie O, Chahin N, Ragole ana.410290421. T, Medvedova E, Silbermann R. Diagnosis of 13. Adams D, Lozeron P, Theaudin M, Denier C, paraproteinemic neuropathy: Room for improvement. J Fagniez O, Rerat K, et al. Varied patterns of inaugural light- Neurol Sci 2020;415:116902. https://doi.org/10.1016/j. chain (AL) amyloid polyneuropathy: a monocentric study jns.2020.116902. of 24 patients. Amyloid 2011;18:98–100. https://doi.org/10 3. Katz JS, Saperstein DS, Gronseth G, Amato AA, .3109/13506129.2011.574354036. Barohn RJ. Distal acquired demyelinating symmetric 14. Cheng RR, Eskandari R, Welsh CT, Varma AK. neuropathy. 2000;54:615–20. https://doi. A case of isolated amyloid light-chain amyloidosis of the org/10.1212/wnl.54.3.615. radial nerve. J Neurosurg 2016;125:598–602. https://doi. 4. Joint Task Force of the EFNS and the PNS. European org/10.3171/2015.10.JNS151095. Federation of Neurological Societies/Peripheral Nerve 15. Mathis S, Magy L, Diallo L, Boukhris S, Vallat J-M. Society Guideline on management of paraproteinemic Amyloid neuropathy mimicking chronic inflammatory demyelinating neuropathies. Report of a Joint Task Force demyelinating polyneuropathy. Muscle Nerve 2012;45:26– of the European Federation of Neurological Societies and 31. https://doi.org/10.1002/mus.22229. the Peripheral Nerve Society--first revision. J Peripher 16. Li J, Li Y, Chen H, Xing S, Feng H, Liu D, et Nerv Syst 2010;15:185–95. https://doi.org/10.1111/j.1529- al. Autonomic Neuropathy and Albuminocytologic 8027.2010.00278.x. Dissociation in Cerebrospinal Fluid As the Presenting 5. Gertz MA. Immunoglobulin light chain amyloidosis: Features of Primary Amyloidosis: A Case Report. Front 2020 update on diagnosis, prognosis, and treatment. Am Neurol 2017;8. https://doi.org/10.3389/fneur.2017.00368. J Hematol 2020;95:848–60. https://doi.org/10.1002/ 17. Chaudhry HM, Mauermann ML, Rajkumar ajh.25819. SV. Monoclonal Gammopathy Associated Peripheral 6. Zingone A, Kuehl WM. Pathogenesis of Neuropathy: Diagnosis and Management. Mayo Clin Monoclonal Gammopathy of Undetermined Significance Proc 2017;92:838–50. https://doi.org/10.1016/j. (MGUS) and Progression to Multiple Myeloma. Semin mayocp.2017.02.003. Hematol 2011;48:4–12. https://doi.org/10.1053/j. seminhematol.2010.11.003. RRNMF Neuromuscular Journal 2021;2(2):41-45 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 44 No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/) Clinic Stuff

18. Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer Journal 2018;8:1–8. https://doi.org/10.1038/s41408-018- 0080-9. 19. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215–24. https://doi.org/10.1038/leu.2008.307. 20. Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121–7. https://doi.org/10.1038/leu.2010.60. 21. Rögnvaldsson S, Turesson I, Björkholm M, Landgren O, Kristinsson SY. Peripheral Neuropathy in MGUS and Progression to Amyloid Light-Chain Amyloidosis: A Population-Based Study Including 15,351 MGUS Cases. Blood 2019;134:5444–5444. https://doi. org/10.1182/blood-2019-131514. 22. Enqvist S, Mellqvist U-H, Mölne J, Sletten K, Murphy C, Solomon A, et al. A father and his son with systemic AL amyloidosis. Haematologica 2009;94:437–9. https://doi.org/10.3324/haematol.13640.

RRNMF Neuromuscular Journal 2021;2(2):41-45 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 45 No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/)